グラチラマー (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "グラチラマー" in Japanese language version.

refsWebsite

Global rank Japanese rank

13nih.gov

4^th place

24^th place

9doi.org

2^nd place

6^th place

4akm.ch

low place

2fda.gov

447^th place

1,043^rd place

2wiley.com

222^nd place

498^th place

1takeda.co.jp

low place

1,105^th place

1pmda.go.jp

6,690^th place

394^th place

1cochrane.org

7,609^th place

low place

1sagepub.com

731^st place

1,777^th place

1medicalnewstoday.com

3,011^th place

8,599^th place

1multiplesclerosisnewstoday.com

low place

1web.archive.org

1^st place

1weizmann.ac.il

4,983^rd place

low place

1mult-sclerosis.org

low place

1nejm.org

2,374^th place

2,486^th place

1neurology.org

9,919^th place

low place

1malariajournal.com

low place

1tandfonline.com

507^th place

1,847^th place

akm.ch

registration.akm.ch

“The REGARD trial: a randomised assessor-blinded trial comparing interferon beta-1a and glatiramer acetate in relapsing-remitting multiple sclerosis”. REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease) study group (2007年10月14日). 2015年9月29日閲覧。
“The REGARD trial: safety and immunogenicity from a randomised, assessor-blinded trial of interferon beta-1a and glatiramer acetate in relapsing-remitting multiple sclerosis”. REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease) study group (2007年10月12日). 2015年9月29日閲覧。
“Betaseron vs. Copaxone in MS with triple-dose gadolinium and 3-T MRI Endpoints (BECOME): announcement of final primary study outcome”. L. Wolansky, S. Cook, J. Skurnick, et al. (2007年10月12日). 2015年9月29日閲覧。
“Betaseron versus copaxone in multiple sclerosis with triple-dose gadolinium and 3 Tesla MRI Endpoints (BECOME): announcement of secondary clinical outcomes”. D. Cadavid, L. Wolansky, S. Cook, et al. (2007年10月12日). 2015年9月29日閲覧。

cochrane.org

Cochrane Database of Systematic Reviews 2004 , Issue 1 . Art. No.: CD004678. DOI: 10.1002/14651858.CD004678^{[リンク切れ]}

doi.org

La Mantia L, Munari LM, Lovati R (2010-05-12). “Glatiramer acetate for multiple sclerosis.”. Cochrane Database Syst Rev. 12 (5): CD004678. doi:10.1002/14651858.CD004678.pub2. PMID 20464733.
Johnson KP, Brooks BR, Cohen JA, et al. (July 1995). “Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group”. Neurology 45 (7): 1268–76. doi:10.1212/WNL.45.7.1268. PMID 7617181.
Johnson KP, Brooks BR, Cohen JA, et al. (March 1998). “Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group”. Neurology 50 (3): 701–8. doi:10.1212/WNL.50.3.701. PMID 9521260.
Ford C, Goodman AD, Johnson K, et al. (March 2010). “Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis : results from the 15-year analysis of the US prospective open-label study of glatiramer acetate”. Multiple Sclerosis 16 (3): 342–50. doi:10.1177/1352458509358088. PMC 2850588. PMID 20106943.
Wolinsky J, Narayana P, O'Connor P, et al. (January 2007). “Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial” (PDF). Ann Neurol 61 (1): 14–24. doi:10.1002/ana.21079. PMID 17262850.
Bornstein MB, Miller A, Slagle S, et al. (1987-08-13). “A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.”. N Engl J Med. 317 (7): 408-14. doi:10.1056/NEJM198708133170703. PMID 3302705.
Comi G, Filippi M, Wolinsky JS (2001-03). “European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.”. Ann Neurol. 49 (3): 290-7. doi:10.1002/ana.64. PMID 11261502.
Lackner P, Part A, Burger C, et al. (February 2009). “Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study”. Malar. J. 8 (1): 36. doi:10.1186/1475-2875-8-36. PMC 2651188. PMID 19250545.
Landa G, Butovsky O, Shoshani J, et al. (2008-11). “Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration.”. Curr Eye Res. 33 (11): 1011-3. doi:10.1080/02713680802484637. PMID 19085384.

fda.gov

accessdata.fda.gov

Prescribing Information (Package insert)^{[リンク切れ]} Label approved on 02/27/2009 (PDF) for COPAXONE, NDA no. 020622 at Drugs@FDA
“FDA Copaxone Label”. FDA (2014年1月28日). 2015年9月29日閲覧。

malariajournal.com

Lackner P, Part A, Burger C, et al. (February 2009). “Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study”. Malar. J. 8 (1): 36. doi:10.1186/1475-2875-8-36. PMC 2651188. PMID 19250545.

medicalnewstoday.com

“Early Treatment With COPAXONE Demonstrated Robust Protection Against Progression To Clinically Definite Multiple Sclerosis In The PreCISe Study”. Medical News Today (2007年12月5日). 2015年9月30日閲覧。

mult-sclerosis.org

Copaxone. All About Multiple Sclerosis.

multiplesclerosisnewstoday.com

“Lipoatrophy Occurrence for MS Patients Higher than Originally Thought”. Multiple Sclerosis News Today (2014年6月18日). 2015年9月30日閲覧。

nejm.org

Bornstein MB, Miller A, Slagle S, et al. (1987-08-13). “A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.”. N Engl J Med. 317 (7): 408-14. doi:10.1056/NEJM198708133170703. PMID 3302705.

neurology.org

Johnson KP, Brooks BR, Cohen JA, et al. (1995-07). “Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.”. Neurology. 45 (7): 1268-76. PMID 7617181.

nih.gov

pubmed.ncbi.nlm.nih.gov

La Mantia L, Munari LM, Lovati R (2010-05-12). “Glatiramer acetate for multiple sclerosis.”. Cochrane Database Syst Rev. 12 (5): CD004678. doi:10.1002/14651858.CD004678.pub2. PMID 20464733.
Johnson KP, Brooks BR, Cohen JA, et al. (July 1995). “Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group”. Neurology 45 (7): 1268–76. doi:10.1212/WNL.45.7.1268. PMID 7617181.
Johnson KP, Brooks BR, Cohen JA, et al. (March 1998). “Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group”. Neurology 50 (3): 701–8. doi:10.1212/WNL.50.3.701. PMID 9521260.
Ford C, Goodman AD, Johnson K, et al. (March 2010). “Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis : results from the 15-year analysis of the US prospective open-label study of glatiramer acetate”. Multiple Sclerosis 16 (3): 342–50. doi:10.1177/1352458509358088. PMC 2850588. PMID 20106943.
Wolinsky J, Narayana P, O'Connor P, et al. (January 2007). “Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial” (PDF). Ann Neurol 61 (1): 14–24. doi:10.1002/ana.21079. PMID 17262850.
Bornstein MB, Miller A, Slagle S, et al. (1987-08-13). “A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.”. N Engl J Med. 317 (7): 408-14. doi:10.1056/NEJM198708133170703. PMID 3302705.
Johnson KP, Brooks BR, Cohen JA, et al. (1995-07). “Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.”. Neurology. 45 (7): 1268-76. PMID 7617181.
Comi G, Filippi M, Wolinsky JS (2001-03). “European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.”. Ann Neurol. 49 (3): 290-7. doi:10.1002/ana.64. PMID 11261502.
Lackner P, Part A, Burger C, et al. (February 2009). “Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study”. Malar. J. 8 (1): 36. doi:10.1186/1475-2875-8-36. PMC 2651188. PMID 19250545.
Landa G, Butovsky O, Shoshani J, et al. (2008-11). “Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration.”. Curr Eye Res. 33 (11): 1011-3. doi:10.1080/02713680802484637. PMID 19085384.

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

“Copaxone (glatiramer acetate) injection, solution”. Daily Med. 2015年9月30日閲覧。

pmda.go.jp

info.pmda.go.jp

“コパキソン皮下注20mgシリンジ添付文書”. PMDA (2020年11月). 2022年1月3日閲覧。

sagepub.com

msj.sagepub.com

Ford C, Goodman AD, Johnson K, et al. (March 2010). “Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis : results from the 15-year analysis of the US prospective open-label study of glatiramer acetate”. Multiple Sclerosis 16 (3): 342–50. doi:10.1177/1352458509358088. PMC 2850588. PMID 20106943.

takeda.co.jp

“多発性硬化症治療剤「コパキソン皮下注20mgシリンジ」の日本における製造販売承認取得について”. 武田薬品工業 (2015年9月28日). 2015年9月30日閲覧。

tandfonline.com

Landa G, Butovsky O, Shoshani J, et al. (2008-11). “Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration.”. Curr Eye Res. 33 (11): 1011-3. doi:10.1080/02713680802484637. PMID 19085384.

web.archive.org

“The chemistry of the Copaxone drug”. Weizmann Institute of Science. 2003年9月7日時点のオリジナルよりアーカイブ。2015年9月30日閲覧。

weizmann.ac.il

“The chemistry of the Copaxone drug”. Weizmann Institute of Science. 2003年9月7日時点のオリジナルよりアーカイブ。2015年9月30日閲覧。

グラチラマー (Japanese Wikipedia)

akm.ch

registration.akm.ch

cochrane.org

doi.org

fda.gov

accessdata.fda.gov

malariajournal.com

medicalnewstoday.com

mult-sclerosis.org

multiplesclerosisnewstoday.com

nejm.org

neurology.org

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

pmda.go.jp

info.pmda.go.jp

sagepub.com

msj.sagepub.com

takeda.co.jp

tandfonline.com

web.archive.org

weizmann.ac.il

wiley.com

onlinelibrary.wiley.com